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Abstract 
Background: Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency is an X‑linked hereditary enzymatic abnormal‑
ity that affects more than 400 million people worldwide. Most deficient individuals do not manifest any symptoms; 
however, several precipitant agents—such as fava intake, infections, or several drugs—may trigger acute haemolytic 
anaemia. Countries should be informed of the prevalence of this enzymatic anomaly within their borders, in order 
to make safe and appropriate national decisions regarding the use of potentially unsafe drugs for G6PD deficient 
individuals.
Methods: A school‑based cross‑sectional survey was conducted in three districts in Mozambique, namely Manhiça, 
located in the south; Mocuba in the centre; and Pemba in the northern tip of the country. G6PD deficiency was evalu‑
ated using the CareStart™ diagnostic test, and enzyme activity levels were measured through fluorescence spectro‑
photometry in deficient individuals. Chi squared and ANOVA tests were used to assess prevalence and mean enzyme 
activity differences, and logistic regression was used to identify risk factors associated to the deficiency.
Results: G6PD deficiency prevalence estimates were lowest in the northern city of Pemba (8.3%) and among 
Emakhuwas and Shimakondes, and higher in the centre and southern regions of the country (16.8 and 14.6%, respec‑
tively), particularly among Elomwes and Xichanganas. G6PD deficiency was significantly more prevalent among male 
students than females (OR = 1.4, 95% CI 1.0–1.8, p = 0.02), although enzyme activity levels were not different among 
deficient individuals from either gender group. Finally, median deficiency levels were found to be more severe among 
the deficient students from the north (0.7 U/gHg [0.2–0.7] p < 0.001) and south (0.7 U/gHg [0.5–2.5]), compared to 
those from the centre (1.4 U/gHg [0.6–2.1]).
Conclusion: These findings suggest that Mozambique, as a historically high malaria‑endemic country has consider‑
able levels of G6PD deficiency, that vary significantly across the country. This should be considered when planning 
national strategies for the use of licensed drugs that may be associated to haemolysis among G6PD individuals, or 
prior to the performance of future trials using primaquine and other 8‑aminoquinolines derivatives.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is an X-linked hereditary enzymatic abnormality that 
affects more than 400 million people worldwide [1]. 
G6PD deficiency (G6PDd) has been historically linked 
to malaria endemic areas due to the believed protection 
that the deficiency offers against Plasmodium infections 
[2–4], specially among heterozygous females [5–7]. This 
deficiency is particularly prevalent in malaria endemic 
areas with the highest peaks in sub-Saharan Africa [8].
G6PD is a cytoplasmic enzyme expressed in all cells, 
involved in the first step of the pentose phosphate path-
way of glycolysis. This enzyme is crucial for the protec-
tion of red blood cells from oxidative stress as it removes 
deleterious oxygen radicals, therefore avoiding prema-
ture erythrocytic lysis [9]. There are approximately 400 
allele variants of the G6PD gene associated with differ-
ent enzyme activity levels. The three most predominant 
variants in sub-Saharan Africa are (i) G6PD type B, cor-
related with a normal enzymatic activity; (ii) G6PD type 
A, coupled with an 85% enzymatic activity; and (iii) 
G6PD type A-associated with severe enzymatic activ-
ity of around 12% [10, 11]. Most deficient individuals do 
not manifest any symptoms; however, agents that cause 
excessive oxidative stress on human bodies can trig-
ger acute haemolytic anaemia, which may often require 
lifesaving blood transfusions if severe [1], or other rarer 
manifestations of disease such as methaemoglobinaemia 
[12]. Precipitant factors include intake of fava beans, spe-
cific drugs, or infections [13, 14].
The most common chemicals associated with hae-
molysis among G6PD deficient individuals include anti-
malarials from the 8-aminoquinoline family, such as 
primaquine, as well as other chemicals such as sulfona-
mides derivatives, dapsone or co-trimoxazole [1, 15, 16]. 
As a result, policies have been developed to avoid det-
rimental safety outcomes after the use of these drugs in 
settings where they are particularly necessary, and where 
the underlying population prevalence of G6PDd may be 
high. This is the case of primaquine (PQ), the currently 
only available 8-aminoquinoline drug, with the potential 
both to interrupt transmission given its efficacy against 
stage V gametocytes, necessary for malaria transmission, 
or to radically cure hypnozoites, responsible for Plasmo-
dium vivax or Plasmodium ovale periodic relapses [14]. 
In this context, the World Health Organization (WHO) 
has recommended a low-dosage of primaquine coupled 
with an effective anti-malarial, for the purpose of inter-
ruption of malaria transmission at community level, that 
is safe for all individuals irrespective or a prior knowledge 
of their G6PD status [17]. However, doses recommended 
for the radical cure of P. vivax or P. ovale hypnozoites 
(7–14 days at higher doses than those recommended to 
interrupt transmission) are still associated with a high 
risk of haemolysis in individuals with severe enzymatic 
deficiency, and such treatment should not be adminis-
tered before ascertaining G6PD status. Aside from pri-
maquine, there are other 8-aminoquinoline derivatives 
in the anti-malarial pipeline, such as tafenoquine, which 
also pose similar challenges among G6PD deficient indi-
viduals [18]. In this context, countries should be informed 
of the prevalence of this enzymatic anomaly within their 
borders, in order to make safe and appropriate decisions 
regarding the use of potentially unsafe drugs for G6PD 
deficient individuals.
Information in Mozambique and the rest of sub-Saha-
ran Africa regarding the frequency and activity level 
of G6PD deficiency is sparse. A study conducted in the 
northern province of Cabo Delgado in 1984 estimated an 
18% prevalence of G6PD deficiency among males [19]. 
Studies conducted in Manhiça, Southern Mozambique, 
identified a proportion of G6PD type A-deficiency of 7.8 
[11] and 10% [20] in a population of males and females, 
and a prevalence of 10% in children less than 5 years of 
age in a hospital-based study in Manhiça (Moraleda 
et  al. pers. comm.). However, another study conducted 
in the city capital of Maputo, also in the south, found a 
18% prevalence among male participants [21]. Given the 
topographical characteristics of Mozambique and its eth-
nic variability, the assessment of the frequency of G6PD 
deficiency in only one part of the country may not be 
representative of the national deficiency prevalence. The 
consequences from this heterogeneity become evident 
when observing differences in the distribution of other 
congenital disorders such as Hb S. In this case, evidence 
from published and unpublished studies identified very 
low Hb S carriers prevalent in the south [20] compared to 
the north of the country [19], which could be explained 
by ethnical heterogeneity. Although it is still unknown 
whether ethnical differences could have affected the dis-
tribution of G6PD deficiency in the same way, they need 
to be considered when measuring its prevalence.
This study aimed to assess the prevalence G6PD defi-
ciency in three different and geographically distinct dis-
tricts of Mozambique, quantify the levels of enzymatic 
activity in these populations, and identify risk factors 
associated to G6PDd.
Methods
Prevalence survey
A school-based cross-sectional survey was conducted in 
three districts in Mozambique, namely Manhiça, located 
in the south; Mocuba in the centre; and Pemba in the 
northern tip of the country (Fig.  1). Study sites were 
selected in order to evaluate the prevalence of G6PD 
in different regions of Mozambique and districts were 
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selected based on logistical convenience. A sample size of 
865 children was calculated per study area to estimate a 
10% G6PDd prevalence with a precision of 2% and a con-
fidence coefficient of 95%.
Two primary and two secondary schools were selected 
per study area. Students of both sexes aged 6  years or 
more attending the selected schools were approached 
and invited to participate in the study. For younger age 
students (6–17 year olds), parents/guardians were asked 
to provide a signed informed consent, and the students 
were also asked to provide their personal assent. Students 
18 years of age or older were directly informed about the 
study, and requested to sign a written informed consent. 
All students who consented to participate in the study 
were included. Siblings or direct cousins of children 
already recruited were excluded from the study to avoid 
estimation bias due to consanguinity. A standardized 
questionnaire was completed for every study participant 
to collect basic demographic information. Ethnicity was 
assessed based on the mother tongue reported.
G6PD deficiency estimates
Qualitative determination of G6PD deficiency was 
determined using the G6PDd CareStart™ rapid diagnos-
tic test (RDT) according to the manufacturer instruc-
tions (AccessBio, New Jersey, USA). This is a qualitative 
enzyme chromatographic test, based on the reduction 
of colourless nitro blue tetrazolium dye to dark coloured 
formazan [22]. Two microlitres of blood were added into 
the sample well and two drops of buffer into the buffer 
well. Results were visually readable after 10–15  min. 
Samples with normal G6PD activity produced a distinct 
purple colour background in the result window, while no 
colour change indicated a deficiency in the G6PD activ-
ity. Deficiency levels detected by this test usually fall bel-
low 2.7 U/gHg of enzymatic activity.
Samples from subjects for whom the CareStart test 
showed a deficiency were used to quantify the residual 
enzyme activity (REA). Samples were processed at the 
Manhiça Health Research Centre (CISM) laboratory and 
conserved using the anticoagulant EDTA at 2–8  °C for 
a maximum of 5  days to guarantee the adequate pres-
ervation of red blood cells until determinations were 
performed.
Quantification of G6PD deficiency was measured using 
the Trinity Biotech quantitative G6PD assay™ (Ref. 345-
UV, Trinity Biotech, St. Louis, USA), following the same 
methodology used to validate the performance of the 
CareStart test [23]. This method uses fluorescence spec-
trophotometry to analyze the rate of NADPH production 
from NADP by the G6PD enzyme from suspended-
erythrocyte samples of 250 μL prepared using the read-
ily available G6PDH assay and substrate reagents. G6PD 
activity was calculated from the increase in absorbance 
detected at 340  nm after 5  min of incubation corrected 
by the temperature of the reaction. The calculation also 
considered the haemoglobin concentration determined 
for each sample prior to spectrophotometry. The result-
ing G6PD activity was validated through a set of three 
controls provided by Trinity Biotech that were processed 
for each individual sample.
G6PD REA outcomes were categorized according to 
the WHO classification guidelines for G6PDd [1]: (i) 
Class I (very severely deficient (associated with chronic 
non-spherocytic haemolytic anaemia, <1% residual activ-
ity, <0.12 U/gHg), (ii) Class II (severely deficient, 1–10% 
residual activity, 0.13–1.2 U/gHg), (iii) Class III (moder-
ately deficient, 10–60% residual activity, 1.3–7.1 U/gHg), 
(iv) Class IV (normal activity, 60–150% residual activ-
ity, 7.2–17.7 U/gHg) and (v) Class V (increased activity, 
>150% residual activity, >17.7 U/gHg) [23].
Statistical analysis
Data were collected using Open Data Kit (ODK) software 
and managed using Stata 13.1 (Stata Corp., College Sta-
tion, TX, USA). Proportions and 95% confidence inter-
vals (CI) were calculated to estimate the prevalence of 
qualitative G6PDd individuals in males and females of 
each study area. Chi squared tests were used to assess 
Fig. 1 Map of study areas in Mozambique
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a proportion difference in G6PDd individuals between 
gender groups for each area separately, and to assess 
the difference of the district-level G6PDd prevalence 
between areas.
Means and standard deviations of the REA spectro-
photometry outcomes from G6PD deficient individuals’ 
were calculated to measure the severity of the defi-
ciency in males and females of every district. Given the 
non-normal distribution of the REA measures obtained, 
Kruskal–Wallis tests were used to assess a difference in 
the median REA of deficient individuals between gender 
groups for each area separately, and of the district-level 
mean REA among areas.
Logistic regression was used to assess the level of asso-
ciation of each potential socio-demographic risk factor 
for RDT-based G6PD deficiency independently. All risk 
factors that were found to have a significant association 
(p value <0.05) to G6PD deficiency in the unadjusted 
model were included in a multi-variable model. To avoid 
multicollinearity caused by introducing area and ethnic-
ity into the same model, two multivariate models were 
created, where the adjusted effect of area and ethnicity 
were separately estimated, controlling for the gender of 
participants. Effect modification parameters were intro-
duced to assess the assumption of a combined asso-
ciation of variables that were believed a priori to have a 
correlated impact, such as the effect of the combination 
of the study area and the participant’s gender. However, 
the introduction of interaction parameters to assess this 
combined effect was not statistically relevant, and effect 
modification was finally excluded from the model. Like-
lihood ratios tests were used to (i) test for effect modi-
fication between the interaction variables, and (ii) assess 
the level of significance of the variables of the multivari-
ate model, adjusted by all the other variables contained in 
the model.
Results
Twelve schools, four per study area, were selected for this 
study, and a total of 2070 participants were recruited. 
Of these, 897 (43%) were from Pemba, 666 (32%) from 
Mocuba, and 507 (25%) from Manhiça. There was a 
slight overrepresentation of female participants in Pemba 
(57%) and in Manhiça (62%), and the mean age of par-
ticipants was 17.9 (SD  =  9.3) years old. The ethnicities 
reported were Emakhuwa (31%) and Shimakonde (6%), 
mostly present in Pemba; Elomwe (5%) in Mocuba; and 
Xichangana (21%) in Manhiça. A proportion of students 
in every study area belonged to other ethnicities, that 
overall represented 17% of the participants. These eth-
nic groups were not considered individually in the analy-
sis due to their low representation in the overall sample 
(less than 5%). Additionally, a fifth (20%) of participants 
reported speaking only Portuguese, which limited our 
ability to assign them a particular ethnicity. Finally, a 
small sample of students (25) reported a history of blood 
transfusions (Table 1).
Of the 2070 individuals recruited, 2026 participants 
consented to be tested using the CareStart™ G6PD defi-
ciency rapid diagnostic test. This analysis found signifi-
cant differences (χ2 test p  <  0.001) between each study 
area’s deficiency prevalence, estimated to be 8.3% (95% 
CI 6.5–10.1) in Pemba, 16.8% (95% CI 13.5–20.1) in 
Mocuba, and 14.6% (95% CI 11.8–17.1) in Manhiça. 
The stratification of G6PDd prevalence by gender in 
each study area revealed that 6.5% (95% CI 4.3–9.1) of 
female students from Pemba were deficient while the 
prevalence of G6PDd in males was significantly higher 
(10.6%, 95% CI 7.5–14.1, p = 0.03). Female students from 
Mocuba and Manhiça also showed lower G6PDd preva-
lence estimates (14.7 and 14.1% respectively) compared 
to their male counterparts (18.9 and 15.4% respectively), 
although these differences were not found to be statisti-
cally different (Table 2; Fig. 2).
Unadjusted logistic regressions identified gender, 
study area and language (as a proxy for ethnicity) as sig-
nificant risk factors for G6PDd diagnosed through Car-
eStart™ RDT (LRT p  <  0.05). Having a history of blood 
Table 1 Demographic characteristics of  the participants 
per study area
a Languages spoken by at least 5% of the study participants overall
Pemba
N (%)
Mocuba
N (%)
Manhiça
N (%)
Total
N (%)
Gender
 Female 509 (57%) 254 (50%) 413 (62%) 1176 (57%)
 Male 388 (43%) 253 (50%) 253 (38%) 894 (43%)
Age
 Mean (SD) 16.44 (7.84) 19.05 (10.24) 18.97 (10.18) 17.89 (9.33)
Transfusion
 No 892 (99%) 496 (98%) 653 (98%) 2041 (99%)
 Yes 5 (1%) 8 (2%) 12 (2%) 25 (1%)
School
 1 210 (23%) 198 (39%) 176 (26%) 584 (28%)
 2 159 (18%) 70 (14%) 69 (10%) 298 (14%)
 3 349 (39%) 190 (37%) 304 (46%) 843 (41%)
 4 179 (20%) 49 (10%) 117 (18%) 345 (17%)
Languagea
 Emakhuwa 602 (67%) 35 (7%) 3 (0%) 640 (31%)
 Shimakonde 126 (14%) 3 (1%) 0 (0%) 129 (6%)
 Elomwe 2 (0%) 98 (19%) 3 (0%) 103 (5%)
 Xichangana 12 (1%) 12 (2%) 408 (61%) 432 (21%)
 Portuguese 28 (3%) 213 (42%) 172 (26%) 413 (20%)
 Other 127 (14%) 146 (29%) 80 (12%) 353 (17%)
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transfusions was not associated to G6PDd (OR  =  0.7, 
95% CI 0.2–2.9) and was, therefore, not considered in 
the multivariate model. Multivariate analysis revealed 
that males were 1.4 (95% CI 1.0–1.8) times more likely 
to be G6PD deficient compared to females. G6PD defi-
ciency was significantly higher in Mocuba (OR  =  2.2, 
95% CI 1.6–3.1) and in Manhiça (OR  =  1.9, 95% CI 
1.4–2.7) compared to Pemba. Similarly, ethnic groups 
mainly prevalent in Mocuba (Elomwe) and in Manhiça 
(Xichangana) were 2.1 times more likely to be G6PD 
deficient compared to the Emakhuwa group from Pemba 
(Table 3).
Samples collected from G6PD deficient individuals 
diagnosed using an RDT were analyzed to evaluate the 
degree of enzyme deficiency. Overall, G6PDd individu-
als from Pemba suffered from severe deficiency (Class II 
according to WHO classification), with a median G6PD 
enzyme activity of 0.7  U/gHg (0.2–0.7  U/gHg), corre-
sponding to 1–10% residual activity. Median enzyme 
activity levels from G6PDd students in Mocuba and 
Manhiça were 1.4 U/gHg (0.6–2.5 U/gHg) and 0.7 U/gHg 
(0.5–2.5  U/gHg) respectively, corresponding overall to 
a moderate deficiency category (10–60% residual activ-
ity) according to WHO guidelines (Class III) in Mocuba 
and a severe deficiency in Manhiça. Nevertheless, REA 
levels ranged from Class II to Class III in both regions. 
Kruskal–Wallis tests revealed no significant differences 
in mean G6PD activities between males and females 
overall (Table 2).
Discussion
This study sheds light over the current prevalence and 
intensity of G6PD deficiency in different regions of 
Mozambique. Results obtained from schools in the 
Table 2 G6PD deficiency measured by the rapid diagnostic test CareStart™, and reactive G6PD enzyme activity of sam-
ples collected from RDT deficient individuals, measured by fluorescence spectrophotometry
* Chi Square or Kruskal–Wallis tests performed to assess the association between gender and G6PD Deficiency for each Area separately
δ Chi Square or Kruskal–Wallis tests performed to assess the association between study area or gender and G6PD Deficiency Overall
a REA assessed only for samples collected form G6PD Deficient Individuals as determined by the CareStart RDT
CareStart G6PD deficiency Reactive G6PD activitya
Total Deficient % (95% CI) χ2 test
p value
Total Median U/gHg (range) Kruskal–Wallis
p value
Pemba
 Females 509 33 6.5 (4.3–9.1) 0.03* 31 0.7 (0.2–0.7) 0.08*
 Males 386 41 10.6 (7.5–14.1) 40 0.7 (0.2–0.7)
 All 895 74 8.3 (6.5–10.1) 71 0.7 (0.2–0.7)
Mocuba
 Females 252 37 14.7 (10.3–19.1) 0.21* 33 1.4 (0.6–2.1) 0.08*
 Males 249 47 18.9 (14.0–24.1) 40 2.1 (0.6–2.1)
 All 501 84 16.8 (13.5–20.1) 73 1.4 (0.6–2.1)
Manhiça
 Females 390 55 14.1 (10.6–18.1) 0.65* 53 0.7 (0.5–2.5) 0.03*
 Males 240 37 15.4 (10.8–20.1) 36 0.6 (0.5–2.5)
 All 630 92 14.6 (11.8–17.1) 89 0.7 (0.5–2.5)
Total
 Females 1151 125 10.9 (9.1–13.1) 0.02δ 117 0.7 (0.2–2.5) 0.57δ
 Males 875 125 14.3 (12.0–17.1) 116 0.7 (0.2–2.5)
 All 2026 250 12.3 (10.9–14.1) <0.001δ 233 0.7 (0.2–2.5) <0.001δ
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Fig. 2 G6PD deficiency prevalence measured using the CareStart™ 
rapid diagnostic test by gender and study area
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northern, middle and southern regions of the country 
suggest that G6PD prevalence varies significantly within 
the country, with the highest prevalence observed in the 
middle (Mocuba, 16.8%), followed by a slightly lower 
prevalence in the south (Manhiça, 14.6%), and the lowest 
prevalence in the north (Pemba, 8.3%).
As expected in a country with endemic malaria, G6PD 
deficiency prevalence estimates resemble those found in 
malaria endemic countries [4, 5, 24]. Mocuba, the area 
that showed the highest G6PDd prevalence in this study, 
belongs to the province of Zambezia, a high malaria-
endemic region currently considered one of the world’s 
malaria hotspots, with recent malaria prevalence esti-
mates at the community level ranging from 66.4% in 2007 
[25] to 54.8% in 2011 [26]. However, G6PDd prevalence 
estimates found in the northern city of Pemba, also a 
malaria hyper-endemic region, are half the magnitude 
of the estimated prevalence in Mocuba, but appear sig-
nificantly different to previous estimates in the area. 
A study performed in Pemba in 1986 showed a G6PDd 
prevalence of 18% among a male study population [19], 
which differs substantially from that found in this study 
among the male students of the same area (10.6%). This 
difference could be attributed to a difference in the sam-
pling frame used to estimate prevalence, or merely due 
to chance. The population of Manhiça showed a G6PDd 
prevalence half way between the estimates that were pre-
viously found in the area (7.8 or 10%) and those meas-
ured in the neighbouring city of Maputo (18%) [21]. This 
confirms that G6PD prevalence is highly population spe-
cific, and thus, attention should be paid to the study pop-
ulation from which future estimates may be withdrawn.
The spatial heterogeneity of G6PD deficiency identified 
here could be partially explained by the ethnical differ-
ences existing within the country. However, as the asso-
ciation found between G6PD deficiency and ethnic group 
was highly correlated to the study site, this analysis was 
unable to make any inference about the effect of ethnic-
ity independent from the region of the country where the 
majority of the ethnic groups are found and vice versa. 
This assessment was also limited by two additional fac-
tors. First, the schools selected for each region belonged 
to relatively urban areas, with higher probability of eth-
nical mixtures and a potential dilution of the associa-
tion between reported ethnicity and enzyme deficiency. 
Second, a significant proportion of the study population 
reported Portuguese as their mother tongue, which hin-
dered the capacity to identify the ethnic group to whom 
those participants belonged. Nevertheless, it is also pos-
sible that the spatial heterogeneity of the deficiency prev-
alence observed was merely due to chance, considering 
particularly the overlap of confidence interval estimates 
between Mocuba and Manhiça, which are substantially 
far away from each other.
Difference in G6PD deficiency rates between gender 
groups were only evident in Pemba, but were not signifi-
cant in the middle and southern regions of the country, 
where the deficiency prevalence overall was also found 
to be higher. These findings correlate with the assump-
tion that as the prevalence of G6PD deficient individu-
als increases in the population, so does the probability of 
finding homozygous female carriers of the deficient gene, 
who will express the deficiency in a more evident form 
[1]. However, regardless of the spatial differences in the 
Table 3 Univariate and  multivariate logistic regression coefficients for  the identification of  risk factors associated 
to G6PD deficiency measured by RDT
a Model adjusted for the variable gender
Risk factors G6PD deficiency Unadjusted Adjusteda
Prevalence (total) 95% CI OR 95% CI OR 95% CI LRT p value
Gender Female 0.11 (1151) 0.09–0.13 1 1 0.02
Male 0.14 (875) 0.12–0.17 1.4 1.0–1.8 1.4 1.0–1.8
Area Pemba 0.08 (895) 0.07–0.10 1 1 <0.001
Mocuba 0.17 (501) 0.14–0.20 2.2 1.6–3.1 2.2 1.6–3.1
Manhiça 0.15 (630) 0.12–0.18 1.9 1.4–2.6 1.9 1.4–2.7
Language Emakhuwa 0.09 (638) 0.07–0.12 1 1 0.002
Shimakonde 0.09 (129) 0.05–0.16 1.0 0.5–2.0 1.0 0.5–1.9
Elomwe 0.17 (103) 0.11–0.26 2.1 1.2–3.8 2.1 1.2–3.7
Xichangana 0.17 (415) 0.14–0.21 2.1 1.4–3.0 2.1 0.5–1.9
Portuguese 0.12 (407) 0.09–0.16 1.4 0.9–2.0 1.4 1.2–3.7
Other 0.13 (334) 0.09–0.17 1.4 0.9–2.2 1.0 0.9–2.2
Transfusion history No 0.12 (1999) 0.11–0.14 1
Yes 0.09 (23) 0.01–0.28 0.7 0.2–2.9
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association between gender and G6PD deficiency, the 
statistical modeling from this analysis identified no sig-
nificant interaction between these two variables, suggest-
ing that gender is still independently associated to the 
deficiency of the G6PD enzyme regardless of the popula-
tion prevalence.
Additionally, this study did not find significant differ-
ences in enzymatic activity estimates between G6PD 
deficient males and females identified through the Car-
eStart test. This is an unsurprising finding considering 
that the test excludes individuals with REA <2.7 U/g Hb) 
[23], which will predominantly include homozygous defi-
cient females and hemizygous deficient males possibly 
with similar REA levels, This is particularly relevant in 
a context when community testing is required to iden-
tify severe deficiencies [27], as one can therefore assume 
that all severe forms of the deficiency will be detected 
regardless of the participant’s gender. The study further 
identified that deficiency levels in the north and south 
were significantly more severe to those in the centre of 
the country. Although it may be a stochastic finding, this 
difference could also be due to the presence of different 
G6PD gene variants across the country, which could con-
fer varying enzyme activity levels among the deficient 
population [10]. However, this study did not conduct 
molecular analysis to identify the variant responsible 
for the observed deficiencies, which limited the capac-
ity to interpret the observed regional patterns of enzyme 
activity levels. In addition, samples for enzyme activity 
determination were only collected for CareStart deficient 
individuals, which possibly limited our capacity to detect 
moderate deficiencies as well as to ensure that all severely 
deficient individuals were been identified by the test.
The results from this study are also subject to other 
limitations. First, the presence of punctual infections 
that cause haemolysis could have affected G6PD activ-
ity levels [13] in study participants who may otherwise 
not be identified as deficient. However, this analysis 
was not able to account for participants’ health status, 
which could lead to an overestimation of the prevalence 
of G6PDd individuals if a sample of participants with 
normal enzyme activity were suffering from haemolysis-
related infections. Second, the study population among 
the three study sites was not homogenously distributed, 
as the northern region contributed to a larger proportion 
of the participants. Nevertheless, this did not affect the 
analysis, given that the estimates were always calculated 
per study area.
Conclusion
This study shows a difference in G6PD deficiency 
prevalence within a sample of Mozambican students 
from three separate regions of the country. Prevalence 
estimates were lowest in the northern city of Pemba 
(8.3%) and among Emakhuwas and Shimakondes, and 
higher in the centre and southern regions of the country 
(16.8 and 14.6% respectively), particularly among Elom-
wes and Xichanganas. G6PD deficiency was significantly 
more prevalent among male students than females, 
although enzyme activity levels were not different among 
deficient individuals from either gender group. Finally, 
deficiency levels were found to be more severe among 
the G6PD deficient students from the north, compared to 
those from the rest of the country. These findings suggest 
that Mozambique, as a historically high malaria-endemic 
country, has considerable levels of G6PD deficiency 
across the country. This should be considered when plan-
ning national strategies for the use of licensed drugs that 
may be associated to haemolysis among G6PD individu-
als, or prior to the performance of future trials using pri-
maquine and other 8-aminoquinolines derivatives.
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